ABCG2 and cancer: VKNG-1, at 6 μM, significantly inhibited p-AKT and Bcl-2 protein expression in the S1-M1-80 cancer cells, suggesting that VKNG-1, in part, reverses ABCG2-mediated drug resistance by decreasing the activation of p-AKT and Bcl-2 without changing Ras, AKT(T), NF-kB p65 expression and P110α, 110β activation.